New lung cancer cocktail trial aims to shrink tumors
NCT ID NCT07622186
First seen Jun 06, 2026 · Last updated Jun 19, 2026 · Updated 4 times
Summary
This phase 2 trial tests a new drug called SKB571 combined with other cancer medicines in 150 people with non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs by injection or mouth, and researchers will monitor side effects and how long the benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan People's Hospital
Dongguan, Guangdong, 523018, China
Contact
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, 350014, China
Contact
-
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, 530021, China
Contact
Contact
-
Guangzhou Medical University First Affiliated Hospital
Guangzhou, Guangdong, 510120, China
Contact
-
Guilin Medical University First Affiliated Hospital
Guilin, Guangxi, 541001, China
Contact
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
Contact
Contact
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
Contact
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
Contact
Contact
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Contact
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
Contact
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
Contact
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
Contact
Contact
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, 030013, China
Contact
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110004, China
Contact
-
Sichuan Cancer Hospital & Institute
Chengdu, Sichuan, 610041, China
Contact
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact
-
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, 710061, China
Contact
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, 300060, China
Contact
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Contact
-
Xiangyang Central Hospital
Xiangyang, Hubei, 441021, China
Contact
-
Xinjiang Medical University Affiliated Tumor Hospital
Ürümqi, Xinjiang Uygur Autonomous Region, 830011, China
-
Xinqiao Hospital of Army Medical University
Chongqing, Chongqing Municipality, 400037, China
Contact
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650118, China
Contact
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SKB571 (injection) combined with osimertinib, furmonertinib, carboplatin, cisplatin, or pembrolizumab
What this could lead to
If it works, this could offer a new combination treatment option to control non-small cell lung cancer and slow its progression.
What could go wrong
This is an early phase 2 trial, so it's not yet proven to work. Side effects from the drug combinations could be serious, and the results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.